• Scynexis Inc SCYX announced the presentation of positive outcomes from the CANDLE 304s nested sub-study of ibrexafungerp in recurrent vulvovaginal candidiasis (RVVC) who failed fluconazole treatment. 
  • The sub-study enrolled 24 patients who failed to respond to an initial three doses of fluconazole over seven days. 
  • Fluconazole failure was defined as persistent vaginal signs and symptoms (VSS) score equal to or greater than three after therapy. 
  • Participants received a one-day treatment of ibrexafungerp (300 mg BID). 
  • Related: Scynexis’s Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections.
  • In this population, 71% of patients (17 of 24) significantly reduced or eliminated signs and symptoms after treatment with ibrexafungerp.
  • Favorable clinical response after a single day of ibrexafungerp was reported in eight of 10 subjects (80%) in this sub-group.
  • In addition, Scynexis recently enrolled the first patient in its Phase 3b study of oral ibrexafungerp for complicated vulvovaginal candidiasis (VVC) in patients who have failed treatment with fluconazole. 
  • In June, the company submitted a supplemental New Drug Application to the FDA for an additional indication for Brexafemme (ibrexafungerp tablets) for the prevention of RVVC. 
  • Price Action: SCYX shares are up 7.71% at $2.23 during the market session on the last check Tuesday.


Source link